Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

Cyclophosphamide 20Brentuximab Vedotin 20fludarabine 16Lenalidomide 13Rituximab 12Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7pirtobrutinib 6Doxorubicin 6Bortezomib 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4venetoclax 3nilotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Diseases × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡